Pre-formed Alloreactivity in Renal Transplant Recipients
Germany190 participantsStarted 2015-11
Plain-language summary
This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on acute rejection episodes and graft outcome in kidney transplant recipients after living donation.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Written informed consent
* First or second renal transplantation
* Living donor renal transplantation
* Recipient older than 18 years
* Negative cross match
* Planed quadruple, Tacrolimus-based (low-dose) immunosuppressive drug regimen (Tacrolimus, 2g MMF starting dose, (methyl)prednisolone according to center practice, basiliximab at day 0 and day 4)
* Planned start of Tacrolimus (Advagraf®) 3 to 10 days prior to transplantation (trough levels 5-10 ng/ml during the first 3 months, 5-7 ng/ml thereafter)
Exclusion Criteria:
* Planed T-cell depleting induction therapy
* Pregnancy
* Pre-existing, moderate to high dose immunosuppressive medication
* Pre-existing, severe lymphopenia (\< 400/µl)